HS knows no boundaries…neither do we
One Voice for HS, everywhere in the world.
We work alongside patients, practitioners, and advocates across the globe — understanding the gaps in HS care and resources, and building what’s needed to fill them.
Who we are
Our mission
“One global organisation, locally rooted. We establish HS Connect hubs and partner with local allies to improve patient care, close resource gaps, and ensure a future where every HS patient is supported and understood.”
What we do
What we’re working toward
Our work is focused on building practical, patient-centered resources and partnerships that help improve HS understanding, access, and support around the world.
Coordinate global campaigns and clinical trial awareness
Develop shared digital resources
Partner on global patient registries
Influence health systems policy
Information sharing
Start here
Helpful HS Connect resources
Explore core HS Connect resources for education, support, advocacy training, research opportunities, and connection.
HS Connect University
Advocacy education and training for patients, mentors, and advocates.
Learn more →What is HS?
Learn the basics of hidradenitis suppurativa, symptoms, diagnosis, and care conversations.
Read the guide →Support Groups
Connect with peer support spaces for people living with HS and their loved ones.
Find support →Clinical Trials
Explore HS research opportunities and learn how clinical trials may support future treatment options.
View trials →International HS clinical trials
Explore HS studies currently recruiting at international locations. Listings update as study information changes.
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
AGE: 18 Years
Status: Recruiting
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
AGE: 18 Years
Status: Recruiting
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
AGE: 18 Years – 100 Years
Status: Recruiting
Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients
AGE: 18 Years – 59 Years
Status: Recruiting
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
AGE: 12 Years – 17 Years
Status: Recruiting
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
AGE: 18 Years – 79 Years
Moderate-to-Severe
Status: Recruiting
Replicative Stress in Hair Follicle Stem Cells and Pathogeny of Hidradenitis Suppurativa
AGE: 18 Years – 99 Years
ALL
Status: Recruiting
SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) (SKINERGY)
AGE: 18+
Moderate to Severe
Status: Recruiting
Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
AGE: 18+
ALL
Status: Recruiting
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) (BE CARING)
AGE: 18+
ALL
Status: Recruiting
A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients
AGE: 18+
Moderate to Severe
Status: Recruiting
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa (MEASUREAAVitHS)
AGE: 12+
Moderate to Severe
Status: Recruiting
A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult Volunteers
AGE: 18+
ALL
Status: Recruiting
A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
AGE: 18+
ALL
Status: Recruiting
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population
AGE: 18+
Moderate to Severe
Status: Recruiting
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib (STOP-LTR)
AGE: 18+
ALL
Status: Recruiting
SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
AGE: 18+
Moderate to Severe
Status: Recruiting
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
AGE: 12+
Moderate to Severe
Status: Recruiting
Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.
AGE: 18+
Moderate to Severe
Status: Recruiting
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
AGE: 18+
Moderate to Severe
Status: Recruiting
Where we work
Our global community
Resources live and in development across 13 countries and regions — with more on the way.
How we work
How do you become part of this?
We go into each country with curiosity — listening first, then building. Every resource we create is grounded in real patient experience and local context.
Listen & learn
We connect with patients and practitioners to understand the real gaps in care and resources in each country.
Build resources
We create translated, culturally relevant education materials — handouts, rack cards, and landing pages in local languages.
Empower advocates
We train emerging patient advocates through HS Connect University, establish HS Connect hubs, and support existing local HS organisations.
Drive change
We coordinate global campaigns and influence health systems policy to improve recognition and care for HS worldwide.